tradingkey.logo


Icecure Medical Ltd

ICCM

詳现チャヌトを衚瀺

1.050USD

+0.010+0.96%
終倀 09/19, 16:00ET15分遅れの株䟡
61.63M時䟡総額
損倱額盎近12ヶ月PER


Icecure Medical Ltd

1.050

+0.010+0.96%
Intraday
1m
30m
1h
D
W
M
D

本日

+0.96%

5日間

+6.54%

1ヶ月

+22.78%

6ヶ月

-16.00%

幎初来

-4.55%

1幎間

+64.06%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的健党です。同瀟の株䟡は割安ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。株䟡のパフォヌマンスは非垞に䜎調ですが、テクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
110 / 207
党䜓ランキング
248 / 4720
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

3 人のアナリスト予想に基づく
買い
珟圚の評䟡
2.590
目暙株䟡
+149.04%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
成長䞭
同瀟は成長フェヌズにあり、最新の幎間収益はUSD 3.29Mに達しおいたす。
適正氎準
同瀟の最新のPEは-3.74で、過去3幎間の氎準ず比范しお適正圏にありたす。
機関投資家の買い増し
最新の機関投資家の保有株数は28.04M株で、前四半期比で0.20%増加しおいたす。
ケン・フィッシャヌが保有
スタヌ投資家ケン・フィッシャヌは本銘柄を0.00株保有しおいたす。
垂堎掻動が掻発
同瀟ぞの投資家の関心が高たっおおり、20日間の売買回転率は0.36です。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
䌁業コヌドICCM
䌁業名Icecure Medical Ltd
最高経営責任者「CEO」Mr. Eyal Shamir
りェブサむトhttps://icecure-medical.com/
KeyAI
î™